![5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one structure, CAS 209410-46-8](/structures/60000/55459_1_209410_46_8.png)
CAS Number209410-46-8
Synonymsvx-745; VX 745; VX745; UNII:TYL52QM320; Neflamapimod; 5-(2,6-Dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6h-pyrimido(1,6-b)pyridazin-6-one
Molecular FormulaC19H9Cl2F2N3OS
Molecular Weight436.26
Purity≥98 (HPLC)%
Density1.6±0.1 g/cm3
Boiling Point578.9±60.0 °C at 760 mmHg
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 209410-46-8 |
| Catalog No. | 2A-9055459 |
| Chinese Name | Neflamapimod |
| Synonyms | vx-745; VX 745; VX745; UNII:TYL52QM320; Neflamapimod; 5-(2,6-Dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6h-pyrimido(1,6-b)pyridazin-6-one |
| Molecular Formula | C19H9Cl2F2N3OS |
| Molecular Weight | 436.26 |
| Purity | ≥98 (HPLC) |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 578.9±60.0 °C at 760 mmHg |
| Appearance | powder |
| Storage Condition | Store at -20°C |
| Application | Neflamapimod (VX-745) is a potent, selective p38α inhibitor with anti-inflammatory activity. |
| HTC | 2933990090 |
| PubChem ID | 329825979 |
| MDL Number | MFCD09834070 |
| SMILES | FC1=C(SC2=NN(C=N3)C(C=C2)=C(C4=C(Cl)C=CC=C4Cl)C3=O)C=CC(F)=C1 |
| InChI | 1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H |
| InChI Key | VEPKQEUBKLEPRA-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| MSDS | msds/55459_1_209410_46_8.pdf |
| Use of | Neflamapimod (VX-745) is a potent and selective inhibitor of p38α, and possesses anti-inflammatory activity. Properties Name 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one Synonym More Synonyms VX-745 Biological Activity Description Neflamapimod (VX-745) is a potent and selective inhibitor of p38α, and possesses anti-inflammatory activity. Related Catalog Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Research Areas >> Inflammation/Immunology References [1]. Duffy JP, et al. The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor. ACS Med Chem Lett. 2011 Jul 28;2(10):758-63. [2]. Pradal J, et al. Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system. Eur J Pharm Biopharm. 2015 Jun;93:110-7. [3]. Bagley MC, et al. Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5107-10. Epub 2007 Jul 13. [4]. Hideshima T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood, 2003, 101(2), 703-705. Chemical & Physical Properties Exact Mass 434.981140 PSA 72.56000 Index of Refraction 1.692 InChIKey VEPKQEUBKLEPRA-UHFFFAOYSA-N Safety Information HS Code 2933990090 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Agrochemical Intermediates | ||
|---|---|---|
| 2-(Trifluoromethyl)-1H-indole-3-acetic acid | 132502-93-3 | 2A-9052209 |
| 2,4-Dichloropyridine-3-carboxaldehyde | 134031-24-6 | 2A-9052326 |
| cis-[2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-4-methylbenzenesulphonate | 134071-44-6 | 2A-9052328 |
| Fenpyroximate | 134098-61-6 | 2A-9052329 |
| Clothianidin | 205510-53-8 | 2A-9055348 |
| 2-(2,4-Difluorophenyl)thiophene | 209592-66-5 | 2A-9055468 |
| 2,4,5-Trifluorophenylacetic acid | 209995-38-0 | 2A-9055487 |
| Flumorph | 211867-47-9 | 2A-9055523 |
| 2,4,5-Trifluorophenylacetonitrile | 220141-74-2 | 2A-9055716 |
| 2,4,5-Trifluorobenzenesulfonyl chloride | 220227-21-4 | 2A-9055719 |
| Browse all Agrochemical Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS